By Dr Steve Arlington and John Wise As part of its mission to help members anticipate and prepare for changes in the pharmaceutical industry, The Pistoia Alliance has developed a research paper which sets out to consider what the life science, biopharma R&D and healthcare ecosystem might… Read More
Unlocking Clinical Trial Data to Uncover New Therapeutic Opportunities By David Wang, Masha Hoffey and Dr Simone Sharma This article discusses opportunities, challenges and best practices in leveraging infrastructure excellence and AI to unlock the value of early or inconclusive clinical trial data. The goal… driving stronger biomarker-based… Read More
Reducing the PAINS in High Throughput Screening: Assay design as a tool for maximising efficiency By Dr Philip S. Jones and Dr Stuart P. McElroy While the quality of the compound collection is frequently described as a key determinant of the success of a high throughput screening… Read More
Optimising Phenotypic Screening – Single-cell analysis versus 3D multicell analysis By Dr Richard M. Eglen In light of the high failure rate of compounds when they are subjected to clinical testing, we are seeing a renaissance in phenotypic screening in drug discovery. However, most phenotypic screening is… Read More
Evolving Models for NASH Drug Discovery: Tools for stemming a silent epidemic By Dr Sue Grepper, Dr Radina Kostadinova, Dr Eva Thoma and Professor Armin Wolf Non-alcoholic fatty liver disease (NAFLD) has quietly become one of the most common causes of chronic liver disease in the modern world. Read More
2030 Life Sciences and Health in the Digital Age (Part 1) By Dr Steve Arlington and John Wise One of the key ways in which The Pistoia Alliance works with its members is to help them not just deal with the problems of today, but also to… Read More
From human genome to global genome – why precision medicine must address genetic diversity By Sumit Jamuar, et al. The publication of the first human genome sequence more than 15 years ago marked the start of a new era in medicine. In the years since then, researchers have… Read More
Fail Early, Fail Fast – A phenotypic rescue approach By Dr Anne-Marie Zuurmond, et al. New disease targets frequently emerge in literature, but the thorough target validation required to consider these targets for a drug discovery programme is often lacking. In pharmacological or genetic perturbation studies… Read More
Automating Automation – How close are we to Artificial Intelligence impact? By Dr Michael A. Tarselli, Dr Yohann Potier and Dr Alan E. Fletcher In terms of consistency, repeatability, known errors and sheer volume, there exists perhaps no better collection of data for computer learning than that… Read More
Application of bioinformatics in support of precision medicine By Mike Furness and John Wise Bioinformatics has played a major role in gene sequencing diagnostics and has been an essential tool to investigate the genetic causes of disease. With the support of new technologies and tools, bioinformatics can play… Read More
How Mergers and Acquisitions Will Drive Oncology Research in 2019 By Dr Michael Seiler 2019 got off to a fast start for oncology drug discovery, with numerous mergers, acquisitions and collaborations announced in quick succession. These ventures provide a window into key trends in oncology research,… Read More
Mining Plant Genomes – A modern approach to herbal healing By Michelle Vierra Plants are stationary soldiers. Rooted to one spot, they are not able to chase nutrients or flee from herbivores and pathogens. So in addition to the basic metabolites they synthesise for their survival, they produce… Read More
From Genotype to Phenotype: Leveraging functional genomics in oncology By Dr Menelas Pangalos & Steve Rees et al. A challenge in drug discovery is that, at best, only around one in five drug candidates will lead to the launch of a medicine. In 2011, AstraZeneca… Read More
How Advanced Automated Liquid Handling Systems are Reshaping Drug Discovery By Helen Stewart-Miller and Dr Richard Massey Winter 2018/19 Once the domain of high-throughput screening (HTS) applications, automated liquid handling systems are now used ubiquitously in drug discovery and have been fundamental in increasing throughput, driving efficiencies… Read More
How Phenotypic CRISPR Screening is Revolutionising Drug Discovery By Dr Steffen Lawo and Dr Carlos le Sage Research in drug discovery and biotechnology increasingly exploits gene editing at industrial scale in order to identify and validate new biological targets for precision medicines. The discovery of CRISPR-Cas9 systems… Read More
Induced Pluripotent Stem Cells (iPSCs) – Unlocking their full potential for Drug Discovery By Abby Edwards and Dr Richard Massey Human stem cells were once viewed primarily as regenerative materials for tissue repair through cell therapies. However, advances in technologies and protocols mean that induced pluripotent stem… Read More